Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C

Journal of Surgical Oncology

Volumn 99, Issue 1, 2009, Pages 32-37

  Sanefuji, Kensaku ^a   Kayashima, Hiroto ^a   Iguchi, Tomohiro ^a   Sugimachi, Keishi ^a   Yamashita, Yo Ichi ^a   Yoshizumi, Tomoharu ^a   Soejima, Yuji ^a   Nishizaki, Takashi ^a   Taketomi, Akinobu ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

HCC; HCV; Hepatoma; IFN; SVR

Indexed keywords

INTERFERON; PROTEIN P53; VIRUS RNA; ANTIVIRUS AGENT; TUMOR MARKER;

AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; BLOOD; LIVER TUMOR; MIDDLE AGED; TUMOR RECURRENCE; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATECTOMY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VIRAL LOAD;

EID: 58149393670     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21176     Document Type: Article

References (36)

1. Bruix J, Barrera JM, Calvet X, et al.: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-1006.
2. Colombo M, Kuo G, Choo QL, et al.: Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008.
3. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium: Global surveillance and control of hepatitis C. J Viral Hepat 1999;6:35-47.
4. Saito I, Miyamura T, Ohbayashi A, et al.: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-6549.
5. Poynard T, Yuen MF, Ratziu V, et al.: Viral hepatitis C. Lancet 2003;362:2095-2100.
6. Reichard O, Andersson J, Schvarcz R, et al.: Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
7. Nishiguchi S, Kuroki T, Nakatani S, et al.: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
8. Hoofnagle JH, Mullen KD, Jones DB, et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
9. Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.
10. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-1539.
11. Reichard O, Glaumann H, Fryden A, et al.: Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999;30:783-787.
12. Yoshida H, Shiratori Y, Moriyama M, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-181.
13. Bruno S, Stroffolini T, Colombo M, et al.: Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-587.
14. Makiyama A, Itoh Y, Kasahara A, et al.: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:1616-1622.
15. Tokita H, Fukui H, Tanaka A, et al.: Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005;20:752-758.
16. Kobayashi S, Takeda T, Enomoto M, et al.: Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: A multicenter, retrospective cohort study of 1124 patients. Liver Int 2007;27:186-191.
17. Chavalitdhamrong D, Tanwandee T: Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006;12:5532-5535.
18. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Tokyo, Japan: KANEHARA; 2003.
19. Ichida F, Tsuji T, Omata M, et al.: Classification report; New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996;6:112-119.
20. Craggs JK, Ball JK, Thomson BJ, et al.: Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA. J Virol Methods 2001;94:111-120.
21. Hsu HC, Tseng HJ, Lai PL, et al.: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness. Cancer Res 1993;53:4691-4694.
22. Sakaguchi Y, Kudo M, Fukunaga T, et al.: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:64-70.
23. Jeong SC, Aikata H, Katamura Y, et al.: Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007;13:5343-5350.
24. Kubo S, Nishiguchi S, Hirohashi K, et al.: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A. randomized, controlled trial. Ann Intern Med 2001;134:963-967.
25. Kawasaki S, Makuuchi M, Miyagawa S, et al.: Results of hepatic resection for hepatocellular carcinoma. World J Surg 1995;19:31-34.
26. Poon RT, Ng IO, Fan ST, et al.: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: A study of a prospective cohort. J Clin Oncol 2001;19:3037-3044.
27. Franco D, Capussotti L, Smadja C, et al.: Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 1990;98:733-738.
28. McHutchison JG, Poynard T, Esteban-Mur R, et al.: Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693.
29. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al.: Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-114.
30. Nigro JM, Baker SJ, Preisinger AC, et al.: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.
31. Cattoretti G, Rilke F, Andreola S, et al.: P53 expression in breast cancer. Int J Cancer 1988;41:178-183.
32. van den Berg FM, Tigges AJ, Schipper ME, et al.: Expression of the nuclear oncogene p53 in colon tumours. J Pathol 1989;157:193-199.
33. Iggo R, Gatter K, Bartek J, et al.: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-679.
34. Koskinas J, Petraki K, Kavantzas N, et al.: Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat 2005;12:635-641.
35. Caruso ML, Valentini AM: Overexpression of p53 in a large series of patients with hepatocellular carcinoma: A clinicopathological correlation. Anticancer Res 1999;19:3853-3856.
36. Cha C, Fong Y, Jarnagin WR, et al.: Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753-758.